Park Medi World Receives Buy Rating as Bed Capacity Expands Across North India

Park Medi World Ltd has drawn fresh attention after Nuvama Wealth Management gave the stock a buy rating. The brokerage set a target price of Rs 280. This suggests a 39.3% upside from Rs 201 on 12th March. The call rests on expansion plans, improving hospital mix, and a valuation gap versus peers.

The group runs a North India hospital platform under PARKHOSP. It operates 14 multi-super-specialty hospitals across Haryana, Punjab, Delhi, and Rajasthan. The network has about 3,250 beds, including about 870 ICU beds. By late 2025, the hospitals were NABH-accredited, according to the note.

A phased pipeline shows total beds rising to around 5,260 by FY28E. That implies about 2,260 new beds and 21% CAGR in FY25-28E. Capacity had already moved from 2,550 beds in FY23 to 3,250 beds by end-December 2025. Management also aims to add about 10,000 beds in five years.

Nuvama expects Tier II cities to drive most growth for Park Medi World. The brokerage cited a better demand-supply gap and faster occupancy scaling there. It also flagged improved capital efficiency versus metro markets. Tier I beds are seen rising from about 1,600 in FY25 to about 1,800 by FY28E.

Tier II capacity is projected to climb from about 1,100 beds in FY25 to about 3,160 by FY28E. This would be about 60% of total beds by FY28E. The shift keeps Tier I relevant for better realisations and brand strength. However, Tier II contributes most incremental capacity, as per estimates.

Segment	FY25 beds (~)	FY28E beds (~)
Tier I	1,600	1,800
Tier II	1,100	3,160

The clinical mix is moving away from general medicine toward higher-acuity care. Cardiology, neurology, and oncology are increasing in contribution. Internal medicine fell to about 30% in H1FY26 from about 41% in FY23. Nuvama linked this shift to better realisations and operating leverage.

Park Medi World is also adjusting its payer mix to lift yields. Revenue share from government programmes and PSUs fell to around 83% in H1FY26. It was about 92% in FY23. Over the same period, self-pay rose to 9% from 4%. Private insurance and TPAs rose to 8% from 3%.

"The Indian healthcare industry is entering a favourable phase with recently added capacities expected to meaningfully contribute to earnings, even as the expansion momentum across the sector stays strong. Against this backdrop, PARKHOSP is well positioned to deliver healthy growth while trading at a reasonable valuation. Over the past two years, most listed hospital companies have seen a significant re-rating, particularly in the affordable healthcare segment. However, PARKHOSP trades at a discount of ~32% to its peer average on an FY27E EV/EBITDA, offering meaningful scope for a valuation catch-up. We expect the valuation gap to narrow driven by faster bed expansions, improving occupancy in core hospitals, a favourable shift in the specialty mix, and a strengthening Balance Sheet. We value the company at 18x FY28E EV/EBITDA, in line with its peer average, to arrive at a TP of INR280," commented the research analysts of Nuvama Wealth Management.

"North India-focused hospital platform Park Medi World (PARKHOSP) is all set to gain from India's structural bed deficit, rising reimbursement dynamics, and faster healthcare growth in Tier II markets. It operates 14 multi-super-specialty hospitals, with ~3,250 beds (including ~870 ICU beds), across Haryana, Punjab, Delhi, and Rajasthan. With a visible expansion pipeline, bed capacity is seen rising to ~5,260 by FY28E led by cluster-based additions in Haryana, Punjab, and NCR, along with its entry into the underpenetrated Uttar Pradesh. This expansion, coupled with a steady shift toward higher-acuity specialties such as cardiology, neurology, and oncology, is resulting in higher ARPOB and operating efficiency. A gradual rebalancing of payer mixes toward higher-yielding private and self-pay segments, besides supportive CGHS rate revisions (a hike of 25-30% effective October 2025), strengthens earnings visibility. We initiate coverage with a 'BUY' rating and TP of INR280," the brokerage further added.

The brokerage also described Park Medi World as the second-largest private hospital chain in North India. It expects cluster-led additions in Haryana, Punjab, and NCR. The plan also includes entering underpenetrated Uttar Pradesh. Separately, CGHS rate revisions were cited as supportive. The note referred to a 25-30% hike effective October 2025.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred to as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.